1215292-27-5

Basic information

• Product Name: 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one
• Synonyms: 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one
• CAS NO: 1215292-27-5
• Molecular Weight: 347.333
• Mol File: 1215292-27-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one(1215292-27-5)
• EPA Substance Registry System: 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one(1215292-27-5)

Safety Data

• Hazardous Substances Data: 1215292-27-5(Hazardous Substances Data)

Upstream product

• 142992-72-1 N-(4-nitrophenyl)guanidinium nitrate 
• 87379-38-2 4-<(dimethylamino)methylidene>-1,3,4,5-tetrahydro-2H-1-benzazepine-2,5-dione 

Relevant articles and documents

Identification of 2-anilino-9-methoxy-5, 7-dihydro-6H-pyrimido[5, 4-d][l]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation

To develop multikinase inhibitors with dual PLK1/VEGF-R2 inhibitory activity, the d-annulated l-benzazepin-2-one scaffold present in the paullone family of kinase inhibitors was investigated as a general structure template suitable for anchoring annulated heterocycles at the hinge region of the ATP binding site. For this purpose, the indole substructure of the paullones was replaced by other nitrogen containing heteroaromatics. The designed scaffolds were synthesized and tested on the indicated kinases. The 2-anilino-5, 7-dihydro-6H-pyrimido[5, 4-d][l]benzazepin-6-ones were found to be VEGF-R2 inhibitors with selectivity against the insulin receptor kinase. The attachment of a methoxy group to the 9-position of the scaffold led to additional PLK1 inhibitory activity, which was explained by an alternative binding mode of the 9-methoxy derivatives. Selected members of the compound class inhibited the VEGF-R2 autophosphorylation in human umbilical vein endothelial cells, the sprouting of human umbilical vein endothelial cell speroids, and the proliferation of diverse cancer cell lines.